CXC趋化因子12（CXCL12）中性配体的前药可预防体内哮喘模型中的炎症反应。
Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo.
作者信息
Gasparik Vincent, Daubeuf François, Hachet-Haas Muriel, Rohmer François, Gizzi Patrick, Haiech Jacques, Galzi Jean-Luc, Hibert Marcel, Bonnet Dominique, Frossard Nelly
机构信息
Laboratoire d'Innovation Thérapeutique, UMR 7200 CNRS/Université de Strasbourg , Faculté de Pharmacie, 74 route du Rhin, 67401 Illkirch, France.
Biotechnologie et signalisation cellulaire, UMR 7242 CNRS/Université de Strasbourg , ESBS, Bld Sébastien Brant, 67412 Illkirch, France.
出版信息
ACS Med Chem Lett. 2011 Dec 9;3(1):10-4. doi: 10.1021/ml200017d. eCollection 2012 Jan 12.
Abstract
Chalcone 4 (compound 1) is a small molecule that neutralizes the CXC chemokine CXCL12 and prevents it from acting on the CXCR4 and CXCR7 receptors. To overcome its poor solubility in aqueous buffers, we designed highly soluble analogues of compound 1, phosphate, l-seryl, and sulfate, all inactive by themselves on CXCL12 but when cleaved in vivo into 1, highly active locally at a low dose in a mouse airway hypereosinophilia model.
摘要
查耳酮4（化合物1）是一种小分子，它能中和CXC趋化因子CXCL12，并阻止其作用于CXCR4和CXCR7受体。为克服其在水性缓冲液中溶解度差的问题，我们设计了化合物1的高溶解性类似物，即磷酸盐、L-丝氨酸盐和硫酸盐，它们自身对CXCL12均无活性，但在体内裂解成1后，在小鼠气道嗜酸性粒细胞增多模型中以低剂量局部具有高活性。
相似文献
1
Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo.
ACS Med Chem Lett. 2011 Dec 9;3(1):10-4. doi: 10.1021/ml200017d. eCollection 2012 Jan 12.
2
Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia.
J Med Chem. 2018 Sep 13;61(17):7671-7686. doi: 10.1021/acs.jmedchem.8b00657. Epub 2018 Aug 28.
3
Decreased Migration of Dendritic Cells into the Jugular-Nodose Ganglia by the CXCL12 Neutraligand Chalcone 4 in Ovalbumin-Sensitized Asthmatic Mice.
Neuroimmunomodulation. 2017;24(6):331-340. doi: 10.1159/000487140. Epub 2018 Apr 20.
4
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in mice.
J Biol Chem. 2013 Apr 26;288(17):11865-76. doi: 10.1074/jbc.M112.449348. Epub 2013 Feb 28.
5
CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Int J Mol Sci. 2021 Jul 9;22(14):7371. doi: 10.3390/ijms22147371.
6
Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Int J Clin Oncol. 2017 Dec;22(6):991-1000. doi: 10.1007/s10147-017-1187-x. Epub 2017 Oct 11.
7
[Role of CXCL12-CXCR4/CXCR7 signal axis in liver regeneration and liver fibrosis].
Zhonghua Gan Zang Bing Za Zhi. 2021 Sep 20;29(9):900-903. doi: 10.3760/cma.j.cn501113-20200721-00403.
8
CXC chemokine receptor 7 (CXCR7) regulates CXCR4 protein expression and capillary tuft development in mouse kidney.
PLoS One. 2012;7(8):e42814. doi: 10.1371/journal.pone.0042814. Epub 2012 Aug 6.
9
Small neutralizing molecules to inhibit actions of the chemokine CXCL12.
J Biol Chem. 2008 Aug 22;283(34):23189-99. doi: 10.1074/jbc.M803947200. Epub 2008 Jun 13.
10
Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Oncogene. 2012 Nov 8;31(45):4750-8. doi: 10.1038/onc.2011.633. Epub 2012 Jan 23.
引用本文的文献
1
Design, Synthesis and Biological Evaluation of Prodrugs of 666-15 as Inhibitors of CREB-Mediated Gene Transcription.
ACS Med Chem Lett. 2022 Feb 17;13(3):388-395. doi: 10.1021/acsmedchemlett.1c00499. eCollection 2022 Mar 10.
2
A Selective Neutraligand for CXCL12/SDF-1α With Beneficial Regulatory Functions in MRL/Lpr Lupus Prone Mice.
Front Pharmacol. 2021 Oct 21;12:752194. doi: 10.3389/fphar.2021.752194. eCollection 2021.
3
An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.
Acta Pharm Sin B. 2021 Sep;11(9):2694-2708. doi: 10.1016/j.apsb.2020.12.005. Epub 2020 Dec 13.
4
Identification of Interleukin-8-Reducing Lead Compounds Based on SAR Studies on Dihydrochalcone-Related Compounds in Human Gingival Fibroblasts (HGF-1 cells) In Vitro.
Molecules. 2020 Mar 18;25(6):1382. doi: 10.3390/molecules25061382.
5
Pharmacological tools to mobilise mesenchymal stromal cells into the blood promote bone formation after surgery.
NPJ Regen Med. 2020 Feb 21;5:3. doi: 10.1038/s41536-020-0088-1. eCollection 2020.
6
Two distinct CXCR4 antagonists mobilize progenitor cells in mice by different mechanisms.
Blood Adv. 2017 Oct 10;1(22):1934-1943. doi: 10.1182/bloodadvances.2017006064.
7
Chalcone Derivatives: Promising Starting Points for Drug Design.
Molecules. 2017 Jul 25;22(8):1210. doi: 10.3390/molecules22081210.
8
The Prodrug Approach: A Successful Tool for Improving Drug Solubility.
Molecules. 2015 Dec 29;21(1):42. doi: 10.3390/molecules21010042.
9
A strategy to discover decoy chemokine ligands with an anti-inflammatory activity.
Sci Rep. 2015 Oct 7;5:14746. doi: 10.1038/srep14746.
10
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in mice.
J Biol Chem. 2013 Apr 26;288(17):11865-76. doi: 10.1074/jbc.M112.449348. Epub 2013 Feb 28.
本文引用的文献
1
Prodrugs--from serendipity to rational design.
Pharmacol Rev. 2011 Sep;63(3):750-71. doi: 10.1124/pr.110.003459. Epub 2011 Jul 7.
2
Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC: A High-Throughput Alternative to log P/log D.
Anal Chem. 1997 Jun 1;69(11):2022-9. doi: 10.1021/ac961242d.
3
Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design.
J Am Chem Soc. 2010 Jun 2;132(21):7242-3. doi: 10.1021/ja1002263.
4
Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications.
Pharmacol Ther. 2010 Apr;126(1):39-55. doi: 10.1016/j.pharmthera.2009.12.003. Epub 2010 Feb 1.
5
French/European academic compound library initiative.
Drug Discov Today. 2009 Aug;14(15-16):723-5. doi: 10.1016/j.drudis.2009.05.012. Epub 2009 Jun 9.
6
Small neutralizing molecules to inhibit actions of the chemokine CXCL12.
J Biol Chem. 2008 Aug 22;283(34):23189-99. doi: 10.1074/jbc.M803947200. Epub 2008 Jun 13.
7
Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
J Med Chem. 2008 Mar 27;51(6):1546-59. doi: 10.1021/jm7011276. Epub 2008 Feb 27.
8
Prodrugs: design and clinical applications.
Nat Rev Drug Discov. 2008 Mar;7(3):255-70. doi: 10.1038/nrd2468.
9
AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation.
Am J Pathol. 2006 Aug;169(2):424-32. doi: 10.2353/ajpath.2006.051234.
10
Synthesis of some pyrazole derivatives and preliminary investigation of their affinity binding to P-glycoprotein.
Bioorg Med Chem Lett. 2005 Oct 15;15(20):4632-5. doi: 10.1016/j.bmcl.2005.05.067.
Zotero 插件